| Trademark Snap Shot Publication Stylesheet (Table presents the data on Publication Approval) |
|||
OVERVIEW |
|||
| SERIAL NUMBER | 88177424 | FILING DATE | 11/01/2018 |
| REG NUMBER | 0000000 | REG DATE | N/A |
| REGISTER | PRINCIPAL | MARK TYPE | TRADEMARK |
| INTL REG # | N/A | INTL REG DATE | N/A |
| TM ATTORNEY | PATE, TARA J |
L.O. ASSIGNED | S10-NOT FOUND |
PUB INFORMATION |
|||
| RUN DATE | 03/20/2020 | ||
| PUB DATE | 04/21/2020 | ||
| STATUS | 681-PUBLICATION/ISSUE REVIEW COMPLETE | ||
| STATUS DATE | 03/19/2020 | ||
| LITERAL MARK ELEMENT | INNOVENT | ||
| DATE ABANDONED | N/A | DATE CANCELLED | N/A |
| SECTION 2F | NO | SECTION 2F IN PART | NO |
| SECTION 8 | NO | SECTION 8 IN PART | NO |
| SECTION 15 | NO | REPUB 12C | N/A |
| RENEWAL FILED | NO | RENEWAL DATE | N/A |
| DATE AMEND REG | N/A | ||
FILING BASIS |
|||||
| FILED BASIS | CURRENT BASIS | AMENDED BASIS | |||
| 1 (a) | NO | 1 (a) | NO | 1 (a) | NO |
| 1 (b) | YES | 1 (b) | YES | 1 (b) | NO |
| 44D | NO | 44D | NO | 44D | NO |
| 44E | NO | 44E | NO | 44E | NO |
| 66A | NO | 66A | NO | ||
| NO BASIS | NO | NO BASIS | NO | ||
MARK DATA |
|
| STANDARD CHARACTER MARK | NO |
| LITERAL MARK ELEMENT | INNOVENT |
| MARK DRAWING CODE | 3-AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/LETTER(S)/NUMBER(S) |
| COLOR DRAWING FLAG | NO |
CURRENT OWNER INFORMATION |
|
| PARTY TYPE | 10-ORIGINAL APPLICANT |
| NAME | Innovent Biologics (Suzhou) Co., Ltd. |
| ADDRESS | Suzhou Industrial Park No. 168 Dongping Street Suzhou City, 215123 |
| ENTITY | 99-limited company (ltd.) |
| CITIZENSHIP | China |
GOODS AND SERVICES |
|
| INTERNATIONAL CLASS | 005 |
| DESCRIPTION TEXT | Medicines for human purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; pharmaceutical preparations, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; drugs in the nature of pharmaceutical preparations for medical purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; chemico-pharmaceutical preparations, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; chemical preparations for medical purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; injectable preparations for medical purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; biological preparations for medical purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; vaccines; diagnostic preparations for medical purposes; dietetic foods adapted for medical use; biological tissue cultures for medical purposes; nutraceutical preparations for use as a dietary supplement for therapeutic or medical purposes |
GOODS AND SERVICES CLASSIFICATION |
|||||||
| INTERNATIONAL CLASS | 005 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
MISCELLANEOUS INFORMATION/STATEMENTS |
|
| CHANGE IN REGISTRATION | NO |
| COLORS CLAIMED STATEMENT | Color is not claimed as a feature of the mark. |
| DISCLAIMER W/PREDETER TXT | THE NON-LATIN CHARACTERS THAT TRANSLITERATE TO "SHENGWUZHIYAO" |
| DESCRIPTION OF MARK | The mark consists of the word INNOVENT; the "O" in "INNOVENT" is comprised of two symmetrical arcs, with Chinese characters beneath the word INNOVENT. |
PROSECUTION HISTORY |
||||
| DATE | ENT CD | ENT TYPE | DESCRIPTION | ENT NUM |
| 03/19/2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | 017 |
| 03/13/2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 016 |
| 03/12/2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 015 |
| 03/12/2020 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | 014 |
| 02/26/2020 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | 013 |
| 02/26/2020 | GNFR | O | FINAL REFUSAL E-MAILED | 012 |
| 02/26/2020 | CNFR | R | FINAL REFUSAL WRITTEN | 011 |
| 08/24/2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 010 |
| 08/23/2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 009 |
| 08/23/2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | 008 |
| 03/11/2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | 007 |
| 03/11/2019 | GNRT | F | NON-FINAL ACTION E-MAILED | 006 |
| 03/11/2019 | CNRT | R | NON-FINAL ACTION WRITTEN | 005 |
| 02/07/2019 | DOCK | D | ASSIGNED TO EXAMINER | 004 |
| 11/17/2018 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | 003 |
| 11/16/2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 002 |
| 11/05/2018 | NWAP | I | NEW APPLICATION ENTERED IN TRAM | 001 |
CURRENT CORRESPONDENCE INFORMATION |
|
| ATTORNEY | Anessa Owen Kramer |
| CORRESPONDENCE ADDRESS | Anessa Owen Kramer HONIGMAN LLP 39400 WOODWARD AVENUE, SUITE 101 BLOOMFIELD HILLS MI 48304-5151 |
| DOMESTIC REPRESENTATIVE | NONE |